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This study was set to investigate antiproliferative potential of dentatin (a natural coumarin isolated from Clausena excavata Burm.
F) against prostate cancer and to delineate the underlying mechanism of action. Treatment with dentatin dose-dependently
inhibited cell growth of PC-3 and LNCaP prostate cancer cell lines, whereas it showed less cytotoxic effects on normal prostate
epithelial cell line (RWPE-1). The inhibitory effect of dentatin on prostate cancer cell growth was due to induction of apoptosis
as evidenced by Annexin V staining and cell shrinkage. We found that dentatin-mediated accumulation of reactive oxygen species
(ROS) and downregulated expression levels of antiapoptotic molecules (Bcl-2, Bcl-xL, and Survivin), leading to disruption of
mitochondrial membrane potential (MMP), cell membrane permeability, and release of cytochrome c from the mitochondria
into the cytosol. These effects were associated with induction of caspase-9, -3/7 activities, and subsequent DNA fragmentation. In
addition, we found that dentatin inhibited TNF-α-induced nuclear translocation of p65, suggesting dentatin as a potential NF-κB
inhibitor. Thus, we suggest that dentatin may have therapeutic value in prostate cancer treatment worthy of further development.
1. Introduction
Prostate cancer is one of the principal causes of mortalities in
men worldwide. Early stage prostate cancer cells are andro-
gen-dependent that can be removed by surgery or antian-
drogen therapy. However, in later stage, malignant prostate
cancer cells show progressive behavior and androgen-inde-
pendency that become insensitive to hormone ablation ther-
apy [1, 2]. Progression of prostate cancer cells is associated
with inhibition of cell apoptosis due to genetic abnormal-
ities in the prosurvival molecules-encoding genes such as
Bcl-2 [3]. Androgen independent cells from prostate cancer
patients showed a remarkably high expression level of Bcl-
2 which prevents apoptosis and renders cells resistance to
chemo- or radiotherapy [4]. Currently, the lack of response
to a wide range of cytotoxic drugs has been a major barrier to
advances in prostate cancer treatment. Therefore, researchers
are working hard to discover new anticancer drugs as ther-
apeutic regimens against prostate cancer.
Medicinal plants are considered one of the hopeful
options for providing new bioactive compounds for the
treatment of cancers [5, 6]. Clausena excavata Burm. F.,
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Figure 1: Chemical structure of dentatin (C20H22O4).
a wild shrub of the Rutaceae family is extensively distributed
inMalaysia, Thailand, and Indonesia. It has been used as folk
medicines for treating cancer and several diseases [7]. This
plant has been reported to possess various biological activ-
ities such as antiinflammatory, antiplatelet, antiplasmodic,
anti microbial, antinociceptive and antiimmunomodula-
tory activities [8–10]. Previous phytochemical investigations
have reported isolation of some carbazole alkaloids and
limonoids. Three known coumarins (nor-dentatin, clauseni-
din, and xanthoxyletin), and six known carbazole derivatives
(3-formylcarbazole, mukonal, 3-methoxycarbonylcarbazole,
murrayanine, 2-hydroxy-3-formyl-7-methoxycarbazole, and
clauszoline J) were also isolated from the plant [11, 12].
In vitro study of structure-activity relationship demon-
strated that cytotoxic activity of coumarins is linked with
derivatives containing ortho-dihydroxy substituents. Addi-
tion of a cathecolic group to the basic structure can increase
its activity in cancer cells [8]. The cytotoxicity of coumarins
is also affected by the presence and positions of the hydroxyls
group [8, 13]. One of the coumarin isolated from C. excavata
is dentatin (5-methoxyl-2′,2′-dimethyl-10-(1,1-dimethyl-2-
propenyl) dipyran-2-one), which is also known as poncitrin
[14]. One study showed that dentatin demonstrated strong
cytotoxicity against activity against human promyelocytic
leukemia (HL-60), human breast cancer (MCF-7), human
cervical cancer (HeLa), and human colon cancer (HT-29)
with IC50 ranging from 5–10 μg/mL [10]. Another investi-
gation by Kawaii et al. [15] reported that dentatin is a potent
cytotoxic agent against human lung carcinoma (A549), mela-
nin pigment producing mouse melanoma (B16 melanoma
4A5), human T-cell leukemia (CCRF-HSB-2), and human
gastric cancer (TGBC11TKB) cell lines. However, the effect of
dentatin on prostate cancer cells has not been reported. Most
importantly, the molecular mechanism underlying antican-
cer activity of dentatin still remained unclear.
The aims of our study are (i) to investigate a potential
therapeutic property of dentatin in prostate cancer cells,
and (ii) to elucidate the molecular mechanism involved in
the dentatin-induced antiproliferation of cancer cells. Here,
we reported the isolation and characterization of dentatin.
Two prostate cancer cell lines PC-3 (androgen-independent)
and LNCaP (androgen-dependent) were included in the
cytotoxicity tests, in comparison with normal prostate
epithelial cells RWPE-1. Morphological changes and strong
Annexin V stain in dentatin-treated prostate cancer cells
suggested the occurrence of apoptotic events. Interestingly,
our data showed that dentatin strongly suppressed prosur-
vival molecules Bcl-2, Bcl-xL, and Survivin. This leads to loss
of mitochondrial membrane potential (MMP) which facili-
tated cytochrome c release and downstream caspase cascade
activation. In addition, we reported dentatin inhibited tumor
necrosis factor-α (TNF-α)-induced nuclear translocation
of nuclear factor-κB (NF-κB), an important transcription
factor which regulates cell proliferation and inflammation.
Finally, we conducted the acute toxicity test of dentatin and
evaluated the drug tolerance dose in rats.
2. Materials and Methods
2.1. Compound Isolation and Identification. C. excavata was
obtained from Pendang, Kedah in December 2010 and was
identified at the Herbarium Unit, Institute of Bioscience,
University Putra Malaysia. A voucher sample of this plant
was deposited in the herbarium of the institute. The roots
(1.5 kg) from C. excavata were air-dried and ground prior
to use. Extraction was done successively with hexane,
chloroform, and methanol at room temperature. The dried
plant materials were extracted at the beginning with six
liters hexane in a big flask (10 L), for 72 h and filtered.
The filtrate was collected and the residues were dried and
extracted with 8 L chloroform, following the same method as
for hexane. The filtrate was collected and the residues were
dried and extracted with 90 % ethanol (8 L) following the
same method as for hexane and chloroform. Different crude
extracts were obtained as a result of socking in increasing
polarities of solvents. The different extracts obtained were
then concentrated using rotary evaporator at 45–50◦C
under reduced pressure and completely dried to yield crude
extracts. The % yield of the crude extracts was calculated
as: (weight of crude extract/weight of fresh plant) × 100%.
Column chromatography over silica gel using a stepwise
gradient elution system was utilized to fractionate the hexane
extract into 8 fractions. Dentatin (C20H22O) was isolated
from fraction 3 as colorless needle-shaped crystal (Figure 1).
The compound was sent for infrared (IR) and nuclear
magnetic resonance (NMR) analyses at the laboratory of
spectroscopic analysis, Faculty of Science, UPM, respectively.
1H and 13CNMR spectral data were recorded in Varian Unity
Inova spectrometer operated at 400 MHz. The chemical
shifts of the respective compound were reported in ppm.1H
NMR spectra were recorded on NMR: Bruker Avance 400
spectrometer apparatus, 13C NMR Spectra were recorded on
Ac 150 MHz instrument and Electron impact Mass spec-
tra (EI-MS) were performed with Finnigan MAT 31 mass
spectrometer with a MATSPECO Data System.
Dentatin: colorless needle-shaped crystal; IR (KBr disc,
Vmax, Cm−1): 1681, 1592, 1460, 1168; 1H-NMR (CDCl3,
400MHz) δ: 1.60 (6H, s, H-16, H-17), 1.70 (6H, s, H-14,
H-15), 3.80 (3H, s, OCH3), 4.60 (1H, dd, J = 10.3, 1.0Hz,
H-13a), 4.62 (1H, dd, J = 17.0, 1.0Hz, H-13b), 5.83 (1H, d,
J = 10.0Hz, H-7), 6.19 (1H, d, J = 9.2Hz, H-3), 6.30 (1H,
dd, J = 17.0, 10.3Hz, H-12), 6.57 (1H, d, J = 10.0 Hz, H-6),
7.80 (1H, d, J = 9.2 Hz, H-4); 13C-NMR (CDCl3, 150 MHz)
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δ: 27.1 (C-16, C-17), 28.6 (C-14, C-15), 40.8 (C-11), 63.0
(OCH3), 76.3 (C-8), 106.8 (C-4a), 107.5 (C-13), 110.6 (C-3),
110.8 (C-5a), 116.1 (C-6), 118.2 (C-10), 130.1 (C-7), 137.9
(C-4), 150.1 (C-12), 151.6 (C-10a), 152.7 (C-5), 157.3 (C-
9a), 161.8 (C-2).
2.2. Cell Lines. Human prostate cancer cell lines PC-3,
LNCaP, and human normal prostate epithelial cells RWPE-
1 were purchased from American Type Culture Collection
(ATCC). PC-3 and LNCaP cells were maintained in RPMI
(Gibco, Carlsbad, CA) with 10% Fetal Bovine Serum (FBS)
supplemented with 100 unit/mL penicillin plus 100 μg/mL
streptomycin. RWPE-1 cells weremaintained in Keratinocyte
Serum Free Medium (K-SFM, ATCC) supplemented with
bovine pituitary extract (BPE) and human recombinant epi-
dermal growth factor (EGF). All cells were cultured in incu-
bator at 37◦C 5% CO2.
2.3. Cytotoxicity Assay. The cytoxicity profiles of den-
tatin were assessed using the 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) microculturetetra-
zolium viability assay [16]. The compound was dissolved
in DMSO to prepare the stock solution and serial dilutions
(0.1 μM–100 μM)were prepared by dissolving the stock solu-
tion in culture media. The final concentration of dimethyl
sulfoxide (DMSO) was kept at 0.1% (v/v). In each plate,
untreated control and blank cell-free control were included.
At designated time after dentatin treatment,MTT (5mg/mL)
was added to each well and the plates were incubated for
4 hours. Media was removed and DMSO was added into
each well to solubilize the formazan crystals. The absorbance
was read at wavelength of 595 nm using a microtitre plate
reader (Tecan Sunrise Basic, Austria). The percentage cellular
viability was calculated with the appropriate controls taken
into account. The concentration which inhibited 50% of
cellular growth (IC50 value) was determined. All experiments
were carried out in triplicates. The inhibitory rate of cell
proliferation was calculated by the following formula:
Growth inhibition = ODcontrol −ODteated sample
ODcontrol
× 100.
(1)
The cytotoxicity of sample on cancer cells was expressed as
IC50 values (the drug concentration reducing the absorbance
of treated cells by 50% with respect to untreated cells).
2.4. Measurement of ROS Generation. The production of
intracellular reactive oxygen species (ROS) was detected
using 2,7-dichlorofluorescin diacetate (DCFH-DA) [17].
DCFH-DA passively enters the cell where it reacts with ROS
to form highly fluorescent compound dichlorofluorescein
(DCF). Briefly, 10mM DCFH-DA stock solution (in meth-
anol) was diluted 500-fold in HBSS without serum or other
additives to yield a 20 μMworking solution. After exposure to
dentatin, the cells in the 96-well black plate was washed twice
with HBSS and then incubated in 100 μL working solution of
DCFH-DA at 37◦C for 30 minutes. Fluorescence was then
determined at 485 nm excitation and 520 nm emission using
a fluorescence microplate reader (Tecan Infinite M 200 PRO,
Ma¨nnedorf, Switzerland).
2.5. Multiple Cytotoxicity Assay. Cellomics Multiparameter
Cytotoxicity 3 Kit was used as described in detail previously
[18]. This kit enables simultaneous measurements in the
same cell of six independent parameters that monitor cell
health, including cell loss, nuclear size, and morphological
changes,MMP changes, cytochrome c release, and changes in
cell membrane permeability. Briefly, 24 hours after dentatin
treatment, MMP dye and the cell permeability dye were
added to live cells and incubated for 30minutes at 37◦C. Cells
were fixed, permeabilized, blocked with 1X blocking buffer
before probing with primary cytochrome c primary antibody
and secondary DyLight 649 conjugated goat antimouse IgG
for 1 hour each. Hoechst 33342 was added into the staining
solution to stain nucleus. Plates with stained cells were
analyzed using the ArrayScan high content screening (HCS)
system (Cellomics, PA, USA). The ArrayScan HCS system is
a computerized automated fluorescence imaging microscope
that automatically identifies stained cells and reports the
intensity and distribution of fluorescence in individual cells.
In each well, 1,000 cells were analyzed. Images were acquired
for each fluorescence channel, using suitable filters. Images
and data regarding intensity and texture of the fluorescence
within each cell, as well as the average fluorescence of the
cell population within the well were stored in Microsoft SQL
database for easy retrieval. Data were captured, extracted
and analyzed with ArrayScan II Data Acquisition and Data
Viewer version 3.0 (Cellomics).
2.6. Measurement of Apoptotic Cells through Annexin V-
Staining. 5× 104 PC-3 or LNCaP cells were seeded overnight
in 96-well plate. Cells were treated with various concentra-
tions of dentatin for 24 h. Annexin V conjugated with fluo-
rescein isothiocyanate (FITC) (BD Pharmingen, San Jose,
CA) were added and further incubated at 37◦C for 15 min-
utes in binding buffer according to the manufacturer’s
instructions. Cells were washed twice with Hank’s balanced
salt solutions (HBSS) before fixing with 4% paraformalde-
hyde. After washing with HBSS, cells were stained with
Hoechst 33342 to visualize nucleus. Annexin V-FITC fluo-
rescence intensity of control or treated samples was analyzed
using the ArrayScan HCS system (Cellomics, PA, USA).
2.7. Bioluminescent Assays of Caspase-3/7, -8 and -9. A time-
dependent study of caspase-3/7, -8, and -9 activities was
performed in triplicates using assay kits Caspase-Glo 3/7, 8,
and 9 (Promega Corp., Madison, WI, USA) on white 96-well
microplate. A total of 10,000 cells per well was seeded and
treated with 7.5 μM of dentatin for 12, 24, and 48 hours.
Then, caspase activity was investigated according to manu-
facturer’s protocol. Briefly, 100 μL of the caspase-Glo reagent
was added and incubated at room temperature for 30 min-
utes. The presences of active caspases from apoptotic cells
will cleave the synthetic tetrapeptide, labeled with aminolu-
ciferin in the reagent. The released aminoluciferin acts as a
substrate for the luciferase enzyme in the reagent to produce
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light, which is measured using Tecan Infinite 200 Pro (Tecan,
Ma¨nnedorf, Swizerland) microplate reader.
2.8. NF-κB Translocation. Cells were seeded overnight at
1.2 × 105 cells/mL concentration in a 96-well plate. The cells
were either pretreated for two hours with different concen-
trations of dentatin or were left untreated. Cells were then
stimulated with 1 ng/mL TNF-α for 30 minutes. The med-
ium was discarded and cells were fixed and stained using
Cellomics nucleus factor-κB (NF-κB) activation kit from
Thermo Scientific according to the manufacturer’s instruc-
tions. The assay plate was evaluated on ArrayScan HCS
Reader. The Cytoplasm to Nucleus Translocation BioAppli-
cation software was used to calculate the ratio of cytoplasmic
and nuclear NF-κB intensity. The average intensity of 200
objects (cells) per well was quantified. The ratios were then
compared among TNF-α-stimulated, dentatin-treated, and
untreated cells.
2.9. Western Blotting. To determine protein expression, 1 ×
106 cells/mL were seeded onto 24 cm2 tissue culture flasks.
Cells were treated with dentatin or paclitaxel for 24 h. Whole
cell extracts were prepared as described by Looi et al. [19].
Briefly, cells were collected and lysed in lysis buffer (20mM
Tris [pH 7.4], 250mM NaCl, 0.1% Triton X-100, 2mM
EDTA, 10 μg/mL leupeptin, 10 μg/mL aprotinin, 0.5mM
phenylmethylsulfonyl fluoride, 4mM sodium orthovana-
date, 1mM DTT). 60 μg of the protein was resolved on 10%
SDS-polyacrylamide gels. After electrophoresis, the proteins
were transferred to PVDF membranes (Millipore). The
membranes were blocked with 5% nonfat dry milk in PBS-T
(0.05% Tween 20) for 1 h at room temperature. Membranes
were probed with primary rabbit anti-Bcl-2, Bcl-xL or Sur-
vivin antibody followed by horseradish peroxidase (HRP)-
conjugated secondary anti-rabbit antibody (Cell Signaling
Technology Inc., CA, USA). Protein-antibody complexes
were detected with Amersham ECL prime Western blotting
detection reagent (GE Healthcare, USA). To ensure equal
loading, membranes were stripped and reprobed with mouse
anti-β-actin antibody (Santa Cruz Biotechnology Inc.).
2.10. Animals. Adult male and female Sprague Dawley rats
(6–8 weeks old) were obtained from the Animal House,
Faculty of Medicine, University of Malaya, Kuala Lumpur.
The rats weighed between 160 and 180 g. The animals were
given standard rat pellets and tap water. Thirty-six rats (18
males and 18 females) were assigned equally into 3 groups
(n = 6 per group) labelled as vehicle (0.5% carboxymethyl
cellulose sodium salt (CMC)), 100 mg/kg and 1000mg/kg of
dentatin preparation. The acute toxicity study was conducted
to determine a tolerable dose for dentatin. The animals were
fasted overnight (but was given drinking water) prior to dos-
ing and further 3 to 4 hours after dosing. The animals were
observed for 30 minutes and at 2, 4, 8, 24, and 48 hours after
intraperitoneal administration of the pure compound for the
onset of clinical or toxicological symptoms. Mortality, if any,
was observed over a period of 2 weeks. The animals were
sacrificed by an overdose of xylazine and ketamine anesthesia
on 15 days following administration of dentatin, and livers
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Figure 2: EI-MS showing presence of molecular ion peak at m/z
326 which corresponds to the molecular formula of C20H22O4.
and kidneys were immediately excised. Histological and
serum biochemical parameters were determined following
standard methods. This study was performed based on
Organization for Economic Co-operation and Development
(OECD)Guideline 420 protocol year 1992, andwas approved
by Institutional Animal Care and Use Committee, University
of Malaya (FAR/30/03/03/2012/IAA(R)).
2.11. Statistical Analysis. Data were presented as mean ±
S.D. Statistical analysis was performed using Student’s t-test
where P < 0.05 was considered to be statistically significant.
3. Results
3.1. Compound Isolation and Identification. Dentatin
(C20H22O4) was isolated as colorless needle-shaped crystal
with 0.21% yield (Figure 1). Spectral data including EI-MS,
1H and 13C NMR were found to be in good agreement
with previous published data [20]. HPLC and LC-MS were
performed to check the purity of the compound (>96.42%).
EI-MS analysis indicated the presence of molecular ion peak
at m/z 326 which corresponded to the molecular formula of
C20H22O4 (Figure 2).
3.2. Dentatin Inhibits Cell Growth of PC-3 and LNCaP Pros-
tate Cancer Cells. To study anticancer potential of dentatin
on prostate cancer cells, we treated PC-3 and LNCaP cells
with various concentrations of dentatin. Cell viability at each
time-point was determined by MTT colorimetric assays. As
shown in Table 1, the half-maximal inhibition concentration
(IC50) readings of dentatin-treated PC-3 cells at 24, 48 or 72
hours were 9.60 ± 1.53 μM, 8.15 ± 2.41 μM, 3.47 ± 0.58 μM,
respectively. Whereas the IC50 of dentatin-treated LNCaP at
24, 48 or 72 hours were 7.32 ± 2.56 μM, 6.79 ± 1.90 μM,
3.76 ± 1.21 μM, respectively. On the other hand, dentatin
showed less cytotoxic effect on RWPE-1 normal prostate
epithelial cell line with IC50 > 20 μM at 24, 48 or 72 hours.
3.3. Dentatin Induces Apoptosis in Prostate Cancer Cells. One
of the earliest features of apoptosis is the translocation of
phophatidylserine from the inner to the outer leaflet of
the plasma membrane, which can be detected by Annexin
V. We stained dentatin-treated or nontreated cells with
Annexin V-FITC and visualized cells under ArrayScan HSC
Evidence-Based Complementary and Alternative Medicine 5
Table 1: Dentatin potently inhibits growth of prostate cancer cells.
IC50 values of prostate cancer cells PC-3 and LNCaP in comparison
to RWPE-1 normal prostate epithelial cells at 24, 48 and 72 hours
post dentatin treatment.
Dentatin (μM)
24 hours 48 hours 72 hours
PC-3 9.60 ± 1.53 8.15 ± 2.41 3.47 ± 0.58
LNCaP 7.32 ± 2.56 6.79 ± 1.90 3.76 ± 1.21
RWPE-1 24.30 ± 2.62 24.98 ± 3.93 22.08 ± 2.68
reader. Annexin V-FITC staining was detected in PC-3 or
LNCaP cells treated with dentatin, but not in the untreated
control cells (Figure 3(a)). In addition, we observed a dose-
dependent increase of Annexin V fluorescence intensities
accompanied by cellular shrinkage in dentatin-treated PC-3
and LNCaP cells (Figure 3(b)).
3.4. Dentatin Induces Nucleus Morphology Alteration.
Nuclear condensation and fragmentation are one of the hall-
marks of apoptosis. Next, we examined nuclear morpho-
logical changes of PC-3 and LNCaP prostate cancer cells by
staining the cells with Hoechst 33342. Results showed that
some treated-cells displayed nuclear condensation and frag-
mentation 48 hours after dentatin treatment (Figure 4(a)).
The nuclear intensity, corresponding to apoptotic chro-
matin changes were significantly increased following den-
tatin treatment in both prostate cancer cells (Figure 4(b),
P < 0.05).
3.5. Dentatin Induces Generation of ROS. ROS forms as a
natural byproduct of the normal metabolism of oxygen.
However, ROS level can increase dramatically upon environ-
mental or chemical stress (e.g., presence of cytotoxic agent).
To examine whether exposure of dentatin promotes ROS
production, we stained live cells with DCFH-DA dye, 24
hours after dentatin treatment. DCFH-DA is rapidly oxi-
dized to DCF by ROS and the fluorescent intensities can be
measured with a fluorescence microplate reader. As shown in
Figure 5, the levels of DCF fluorescence in PC-3 and LNCaP
cells treated with dentatin were significantly increased in a
dose-dependent manner.
3.6. Multiparameter Cytotoxicity Analysis
3.6.1. Dentatin Induces Alterations on MMP and Cell Mem-
brane Permeability. The mitochondria are the main source
of cellular ROS, adenosine triphosphate (ATP), and key
regulators of mechanisms controlling cell survival and death.
Fluorescent probes for monitoring MMP are frequently used
for assessing mitochondrial function. As shown in Figure 6,
MMP dye stained strongly and diffusely in the cytoplasm
of control cells compared to 15 μM dentatin-treated cells
(Figure 6). PC-3 or LNCaP cells treated with various con-
centration of dentatin for 24 hours showed dose-dependent
reduction of fluorescence intensity (Figure 7(a)), which
reflected the collapse of MMP. In addition, we observed a
significant increase in cell membrane permeability in den-
tatin-treated cells (Figures 6 and 7(b)).
3.6.2. Dentatin Induces Release of Cytochrome c to Cytosol.
Cytochrome c is an important mediator of apoptosis pro-
gram. Apoptotic stimulus triggers the release of cytochrome
c from the mitochondria into cytosol where it binds to Apaf-
1 to form apotosome and activates caspase cascade [21].
Cytochrome c stained weakly and diffusely in control cells.
In contrast, dentatin treated-PC-3 or LNCaP showed strong
staining around the nucleus (Figure 6). This suggests that
treatment of prostate cancer cells with dentatin triggered
the translocation of cytochrome c from mitochondria into
the cytosol. Occasionally we detected cytochrome c in
the nucleus of dentatin-treated cells but not in control
cells (Figure 6). When treated cells with increasing con-
centrations of dentatin, we observed that dentatin dose-
dependently induced cytochrome c release compared to
control (Figure 7(c)).
3.7. Dentatin Elevates Caspase-3/7 and -9 Activities. The
release of cytochrome c from mitochondria activates down-
stream caspase molecules and lead to apoptotic cell death.
To examine this, we measured the bioluminescent intensities
of caspase-3/7, -8, -9 activities of dentatin-treated PC-3 and
LNCaP cells at 12, 24, or 48 hours time-point. As shown
in Figure 8, significant increased in caspase-3/7, -9 activi-
ties were detected after 12 and 24 hours of dentatin expo-
sure. On the other hand, caspase-8 activity was not affected.
Thus, these data suggest that dentatin-induced apoptosis in
PC-3 and LNCaP is mediated via the intrinsic (mitochon-
drial-caspase-9) pathway, but not extrinsic (death receptor-
caspase-8) pathway.
3.8. Dentatin Treatment Reduces Expression of Antiapoptotic
Molecules. It is well established that antiapoptotic proteins
(Bcl-2, Bcl-xL, Survivin) play an important role in maintain-
ing MMP and preventing apoptosis in cancer cells. To deter-
mine the underlying mechanism of dentatin-induced apop-
tosis, the expressions of apoptosis-related proteins were
investigated. Interestingly, western blot results showed strong
reduction in the expression level of antiapoptotic molecules
Bcl-2, Bcl-xL, and Survivin in dentatin-treated PC-3 and
LNCaP cells compared to control (Figure 9). Together, these
results indicate that dentatin induced apoptosis via the
mitochondrial-pathway by downregulating Bcl-2, Bcl-xL,
and Survivin protein levels in prostate cancer cells.
3.9. Dentatin Suppresses TNF-Induced NF-κB Translocation.
The transcription factor NF-κB plays a central role in
inflammation and cancer. Activation of NF-κB in response
to inflammatory cytokine such as TNF-α promotes nuclear
migration to enable DNA-binding activity and facilitate
target genes expression (e.g., Bcl-xL and Survivin). In control
cells, TNF-α-stimulation led to NF-κB translocation from
the cytoplasm to the nucleus (Figure 10(a)). Treatment of
PC-3 or LNCaP prostate cancer cells with dentatin blocked
NF-κB translocation and resulted in accumulation of NF-
κB in the cytoplasm after TNF-α stimulation (Figure 10(a)).
Statistical analysis revealed a significant dose-dependent
inhibition of TNF-α-mediated nuclear NF-κB translocation
by dentatin (Figure 10(b)).
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Figure 3: Dentatin induces apoptosis in prostate cancer cell lines. (a) PC-3 and LNCaP cells were treated with 15 μM of dentation for
24 hours. Cells were stained with Hoechst 33342 for nucleus and Annexin V-FITC to detect apoptotic cells. (b) Fluorescence intensity of
Annexin V in PC-3 or LNCaP cells treated with designated concentration of dentatin. Data were shown as mean± SD. Significant differences
(∗P < 0.05) between dentatin-treated and untreated control cells.
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Figure 4: Nucleus damage in dentatin-treated prostate cancer cells. (a) Representative images of PC-3 and LNCaP cells treated with medium
alone or with 15 μMdentatin, and stained withHoechst 33342 for nucleus. Arrows showing condensed or fragmented nucleus. (b) Histogram
showing fluorescence intensity of nucleus in PC-3 and LNCaP cells treated with various concentrations of dentatin or 10 μM paclitaxel, an
anticancer drug. Data were shown as mean ± SD. (∗P < 0.05).
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3.10. Acute Toxicity Study of Dentatin In Vivo. To date, no
study has been conducted to investigate the tolerable dosage
of dentatin in an animal model.To evaluate whether dentatin
could induce adverse effects in vivo, both male and female
rats were injected intraperitoneally with dentatin in doses
of 100mg/kg or 1000mg/kg. Control and treated rats were
observed for 14 days. All treated rats remained alive and did
not manifest any visible toxicity signs at any of the doses.
Histopathology assessment showed normal phenotypes of
liver and kidney in rats administrated with dentatin when
compared to control rats (Figure 11). Analysis of serum
biochemistry profile for hepatic functional tests (Table 2)
and renal functional tests (Table 3) did not show any
significant changes between vehicle-treated and dentatin-
treated rats. Thus, our result showed that intraperitoneal
50% lethal dose (LD50) value for both female and male rats
is greater than 1 g/kg.
4. Discussion
The androgen receptor helps prostate cancer cells to survive
and is a target for many anticancer research studies. Andro-
gen ablation therapy using luteinizing hormone-releasing
hormone agonists (LH-RH) has become a primary treatment
formetastatic prostate cancer [22]. LH-RH antagonist Cetro-
relix inhibits the growth of PC-3 through downregulation of
EGF receptors whereas antiandrogen Flutamide affects the
expression of protein kinase C (PKC) which is important
for prostate cancer cell growth [23, 24]. Anti-androgens are
frequently used in conjunction with androgen ablation ther-
apy as a combined androgen blockade to improve therapeu-
tic outcome [25]. However, prostate cancer cells may survive
androgen deprivation therapies by increasing androgen
receptor expression or intracrine androgen synthesis within
the prostate [26, 27]. So far, inhibiting the androgen recep-
tor has only proven to be effective in mouse studies
[28]. On the other hand, dentatin induced apoptosis
through downregulation of Bcl-2, Bcl-xL, Survivin, activa-
tion of caspase cascade and inhibition of NF-κB nuclear
translocation in PC-3. Our results revealed that dentatin
showed strong cell-growth inhibition against PC-3 (andro-
gen receptor-negative; androgen-resistant) [29] and LNCaP
(androgen receptor-positive; androgen-dependent) [30],
implying that dentatin-induced apoptosis in prostate cancer
cells is not dependent on androgen sensitivity of the cells.
Normal prostatic epithelium undergoes apoptosis after
androgen withdrawal. In contrast, androgen deprivation of
LNCaP resulted in cell growth arrest for prolonged time
periods without morphological evidence of cell death [31].
It was found that androgen deprived LNCaP cells can resist
apoptosis by increasing Bcl-2 expression [31]. Interestingly,
these LNCaP cells undergo apoptosis when treated with
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Figure 7: Multiparameter cytotoxicity analysis of dentatin-treated PC-3 and LNCaP cells. Histogram showing the average fluorescent
intensities for (a) MMP, (b) cell membrane permeability, and (c) cytochrome c. Dose-dependent decreased of MMP with increased of
cell membrane permeability and cytochrome c average fluorescent intensities were observed in dentatin-treated cells. Data were shown as
mean ± SD. Significant differences (∗P < 0.05) between dentatin-treated and untreated control cells.
cytotoxic drug etoposide [31]. In this study, we showed
that dentatin induced cell death in LNCaP and PC-3 cancer
cells by targeting antiapoptosis proteins Bcl-2 and Bcl-xL.
The oncoproteins Bcl-xL and Bcl-2 have been associated
with the development of androgen-independent prostate
cancer which affects chemosensitivity in advanced stages of
the pathology [4, 32]. Bcl-2 is linked to prostate cancer
progression because upregulation of Bcl-2 was observed after
androgen ablation in prostate carcinoma cell lines and in
castrated-male rat model [4]. Based on these observations,
it was suggested that combining chemotherapeutic agents
(such as dentatin) with androgen blockade may have ther-
apeutic advantage over hormone ablation alone [33].
In the present study, we showed that dentatin induces
substantial repression of Survivin, which may correlate with
high apoptotic rate in LNCaP and PC-3 prostate cancer cells.
Survivin is amember of the inhibitor of apoptosis (IAP) fam-
ily and is frequently upregulated in cancer and lymphoma
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Figure 8: The activities of caspase-3/7, -8, and -9 in dentatin-treated prostate cancer cells. PC-3 and LNCaP cells were untreated or treated
with dentatin for 12, 24, and 48 hours. Bioluminescent assays for caspase-3/7, -8, -9 activities were performed as described in Section 2. Data
were shown as mean ± SD.
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Figure 9: Dentatin decreases pro-survival molecules of prostate cancer cells. PC-3 and LNCaP were treated with control DMSO, control
drug paclitaxel or dentatin. Cell lysates collected were resolved with SDS-PAGE gel, blotted onto membrane, and probed with antibodies
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Table 3: Renal function test. Male and female rats received vehicle (CMC), 100mg/kg or 1000mg/kg dentatin for 14 days. Renal function
was examined by measuring serum level of sodium, potassium, chloride, CO2, anion gap, urea and creatinine.
Dose
Sodium
(mmol/L)
Potassium
(mmol/L)
Chloride
(mmol/L)
CO2
(mmol/L)
Anion gap
(mmol/L)
Urea
(mmol/L)
Creatinine
(μmol/L)
Male rats (n = 6)
Vehicle (CMC) 142.05 ± 3.58 4.89 ± 0.07 104.01 ± 2.87 24.85 ± 1.85 18.11 ± 0.58 5.50 ± 0.38 34.88 ± 2.38
Dentatin 100mg/kg 142.03 ± 2.54 5.00 ± 0.06 107.13 ± 2.03 22.60 ± 1.19 18.17 ± 0.61 6.20 ± 0.20 33.67 ± 2.65
Dentatin 1000mg/kg 144.50 ± 3.86 4.95 ± 0.05 105.17 ± 2.58 21.56 ± 1.05 17.32 ± 0.45 5.63 ± 0.39 36.13 ± 4.90
Female rats (n = 6)
Vehicle (CMC) 141.53 ± 4.410 4.66 ± 0.12 105.38 ± 2.67 23.38 ± 1.47 18.01 ± 0.86 7.98 ± 0.35 41.89 ± 3.75
Dentatin 100mg/kg 141.00 ± 3.68 4.75 ± 0.16 107.53 ± 3.68 22.95 ± 0.95 17.13 ± 1.71 8.11 ± 0.24 42.34 ± 4.76
Dentatin 1000mg/kg 142.27 ± 4.47 4.54 ± 0.13 106.00 ± 3.63 22.58 ± 1.78 18.17 ± 1.49 8.31 ± 0.69 44.05 ± 2.15
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Figure 10: Dentatin inhibits TNF-α-induced NF-κB nuclear translocation in prostate cancer cells. (a) Representative images of NF-κB
localization in the cellular compartment of PC-3 and LNCaP cells without stimulation (TNF-α−), with 10 ng/mL TNF-α stimulation alone
(TNF-α +) or treated with 15 μM of dentatin after 10 ng/mL TNF-α stimulation. Cells were stained with Hoechst 33342 for nucleus (blue).
NF-κB (green) was stained as described in Section 2. 20x magnification. (b) Histogram showing quantitative fluorescence intensity analysis
of NF-κB in the nucleus of PC-3 and LNCaP without stimulation (TNF-α−), with 10 ng/mL TNF-α stimulation alone (TNF-α +) or treated
with various concentrations of dentatin after 10 ng/mL TNF-α stimulation. Dentatin treatment caused a dose-response decreased of TNF-
α-induced NF-κB nuclear translocation in PC-3 and LNCaP cells. Data were shown as mean ± SD. Significant differences ∗P < 0.05 were
determined by comparing samples to the TNF-α stimulated cells (TNF-α +).
cells [34]. Survivin binds to caspases activation and blocks
cell death induced by a variety of stimuli [35]. Disruption of
Survivin leads to increase in caspase-3-dependent apoptosis
and demonstrated significant anti-tumor activity in multiple
cancer cells in vitro and in vivo xenograft models [36]. It
has been reported that development of hormone resistance
in prostate cancer is linked to upregulation of Survivin
and targeting Survivin would sensitize prostate cancer cells
to antiandrogen therapy [37]. Currently, Survivin antisense
inhibitor LY2181308 is evaluated in Phase II clinical trial for
prostate cancer [36].
Mammalian cells have two main pathways that lead
to apoptosis, namely extrinsic and intrinsic pathways. The
extrinsic is initiated by extrinsic ligand binding to death
receptors, such as Fas (CD95), which in turn activates
caspase-8 [38]. The intrinsic mitochondrial pathway is
regulated by Bcl-2 family proteins [39, 40]. Downregulation
of Bcl-2 or Bcl-xL could lead to permeabilization of mito-
chondrial outer membrane and facilitate the release of mito-
chondrial cytochrome c into cytoplasm [41]. Cytochrome c
bind to Apaf1 and caspase-9 to form a multiprotein complex
called apoptosome, which functions to execute apoptotic
process [21]. Apoptosome triggers activation of caspase-
3/7, which cleaves its substrate poly(ADP-ribose) polymerase
(PARP), a nuclear enzyme important for DNA repair [42].
Excessive ROS can also induce oxidative damage of DNA,
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Figure 11: Liver and kidney histology of control and dentatin-
treated animals. Wildtype rats were treated intraperitoneally with
vehicle (CMC) only or with dentatin at concentrations 100 or
1000mg/kg for 14 days. Liver and kidney were fixed, sectioned, and
stained with Hematoxylin and Eosin. No significant signs of toxicity
were observed in the liver and kidney histological sections of treated
rats. Magnification 20x.
including strand breaks and nucleotide modifications [43].
Thus, high ROS generated by dentatin coupled with inac-
tivation of a proper DNA repair molecule such as PARP
by caspase-3 cleavage could result in DNA fragmentation
leading to irreversible cell death in prostate cancer cells.
The development of prostate cancer from nonmalignant
prostate is a lengthy process that may take several years and
is often related to diet, lifestyle habit, and chronic inflam-
mation [44]. Studies showed that consuming dietary rich in
chemopreventive compounds that inhibit NF-κB can pre-
vent prostate carcinogenesis [45, 46]. NF-κB is a key
regulator of numerous inflammatory cytokines [47]. Upon
TNF-α stimulation, the IκB kinase complex (IKK) becomes
activated, leading to the translocation of NF-κB to the
nucleus [48]. In this study, we showed dentatin could impede
TNF-α-induced NF-κB nuclear translocation. Thus, dentatin
could be a potential chemopreventive molecule to block
prostate cancer initiation or progression by inhibiting NF-
κB-mediated inflammation. In addition, NF-κB is known as
antiapoptotic factor as it is implicated in the transcriptional
activation of proteins promoting cell survival such as Bfl1,
Nr13, IAPs, Bcl-xL and Survivin [49]. Several publications
have suggested NF-κB to be the causative gene responsible
for mediating resistance to apoptosis in prostate cancer [50].
The ability of dentatin to promote prostate cancer cell death
by inhibiting NF-κB transactivation could be useful in com-
bination with conventional therapy [51].
Preclinical acute toxicological evaluation is necessary to
establish safety profiles for drugs of herbal origin. To the best
of our knowledge, this is the first report on acute toxicity
study of dentatin in vivo. Our results indicated that dentatin
in doses of 100 and 1000mg/kg did not produce any deaths
or clinical signs of toxicity in both female- and male-treated
rats. Assessment of renal function tests (e.g., plasma urea and
creatinine levels) and liver function tests (e.g., AST and ALT
levels, biomarkers of liver injury) showed no significant alter-
ation between control and treatment groups. Further histo-
logical assessment of kidney and liver revealed no detri-
mental changes in these organs. Based on these results, we
defined that single dosage of 1 g/kg of dentatin as the no-
observed-adverse-effect level (NOAEL) for Sprague Dawley
rats of both sexes under the experimental conditions used.
In comparison, paclitaxel (widely used anti-cancer drug) at
dosage of 20mg/kg causes hind-limb paralysis in treated
mice, indicating high paclitaxel dosages may pose serious
side effect and cause damage to the nerves innervating the
hind-limb muscle [52].
5. Conclusion
In the present study, we showed that dentatin-induced apop-
tosis by modulating expression level of antiapoptotic mole-
cules Bcl-2, Bcl-xL, Survivin, activation of mitochondrial-
dependent caspase cascade and inhibition of NF-κB nuclear
translocation in human prostate cancer cells. Moreover,
acute toxicity tests by intraperitoneal administration of up
to 1 g/kg in rats did not show any biochemical, anatomical,
or histopathological signs of toxicity, suggesting dentatin is
relatively tolerable in vivo. Currently, works are ongoing to
evaluate the anti-cancer efficacy of dentatin inmice xenograft
model.
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